국제성모병원 내용 바로가기 링크

Introducing Amyloid PET-CT

HIT : 4,836DATE : 2016-08-30

Catholic Kwandong University Internatinal St. Mary’s Hospital has recently introduced PET-CT(positron emission tomography)for an early detection of Alzheimer’s diseases.

 

Test of ‘F-18 Flutemetamol PET-CT’(so-called Amyloid PET-CT) shows image of distribution width of beta-amyloid neural plate inside of the brain, which is prevalent in patient with Alzheimer’s diseases.

 

Beta amyloid, toxic proteins, is known to cause Alzheimer’s diseases, and can cause various brain diseases including Alzheimer’s diseases as it builds up inside the brain. F-18 Flutemetamol, used as radiopharmaceutical, combines with beta-amyloid, and the test shows the image of beta amyloid, deposited inside the brain. An existing PET-CT shows the cross-sectional area of beta amyloid only in black and white, while F-18 Flutemetamol PET-CT raised the efficiency of diagnosis by showing the image in color.




 

  [A photo]Catholic Kwandong University International St. Mary’s Hospital PET-CT

 

In addition, the test does not require fasting and agents will be administered for imaging of beta amyloid. After 90 minutes of rest after the agent is injected, the test will be perfomed for about 20 minutes. Safety and validity of test have been already proven through approvals by the U.S. Food and Drug Administration(2013) and the European Medicines Agency(2014). As well, the test obtained item permission on August, 2015 and received new medical technology evaluation on Feburary, 2016.

 

With the introduction of F-18 Flutemetamol PET-CT, it became much easier to distinguish Alzheimer’s diseases from other kinds of demetias as well as the test can early detect Alzheimer’s diseases.